[Form 4] CRISPR Therapeutics AG Insider Trading Activity

Rhea-AI Filing Summary

On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.

Positive

• Transparent disclosure of officer/director transaction filed on Form 4
• Disposition was charitable (donor-advised fund) rather than a sale for cash
• Timely filing and signature indicating compliance with Section 16 reporting

Negative

• Direct beneficial holdings decreased by 6,000 shares following the donation

Insights

Corporate Governance Expert

TL;DR: Routine charitable disposition by CEO/director; reduces direct holdings modestly and is disclosed per Section 16 rules.

The filing documents a non-sales disposition of 6,000 common shares via a donor-advised fund, complying with Section 16 reporting requirements. As both an officer and director, transparent disclosure is important to avoid appearance of undisclosed insider trading. The remaining direct and indirect holdings are clearly stated, with the indirect interest held through a 2023 grantor retained annuity trust (GRAT), which is common for estate planning and does not alter voting disclosure requirements.

Securities Compliance Analyst

TL;DR: Transaction appears routine and non-material to investors; no cash proceeds reported.

The Form 4 records a Code G transaction (bona fide gift) of 6,000 shares with a reported price of $0.00, indicating a charitable contribution rather than a market sale. Reporting shows 201,004 direct shares and 85,622 indirect shares via the Kulkarni 2023 GRAT. The timely filing and manual signature satisfy reporting formalities; there are no derivative or option transactions disclosed on this form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/17/2025		G		6,000(1)	D	$0.00	201,004	D
Common Shares								85,622	I	The Kulkarni 2023 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person made a charitable contribution of common shares to a donor advised fund.

	/s/Samarth Kulkarni	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Samarth Kulkarni report on the Form 4 for CRSP?

He reported a Code G charitable disposition of 6,000 common shares on 09/17/2025 and a post-transaction direct holding of 201,004 shares.

Was the transaction a sale that generated cash proceeds?

No; the Form 4 lists the price as $0.00, indicating a donation to a donor-advised fund rather than a sale for proceeds.

Does Kulkarni hold additional CRSP shares indirectly?

Yes; the filing discloses 85,622 shares held indirectly through the Kulkarni 2023 GRAT.

What roles does the reporting person hold at CRISPR Therapeutics?

The Form 4 indicates Samarth Kulkarni is both a Director and the Chief Executive Officer of CRSP.

Is there any derivative or option activity reported on this Form 4?

No; Table II for derivative securities shows no derivative or option transactions disclosed on this filing.